Reported net loss of $57.5 million and EPS of $(0.65) for Q3 2025, with no collaboration revenue against consensus of $0.727M.
Cash and cash equivalents increased to $272.6 million from $143.4 million prior year, bolstered by $161.7M public offering and $44.9M ATM proceeds.
R&D expenses rose to $49.2 million due to pipeline advancement; cash runway extends into 2027.
IM-3050 Phase 1 trial initiation delayed to early 2026 from late 2025 due to radiotracer supply issues.
Earnings announced on November 6, 2025, via 8-K filing with press release as Exhibit 99.1.